Drug metabolism

Boehringer Ingelheim Expands Usage of Genedata Biologics to DMPK Operations

Retrieved on: 
Monday, November 20, 2023
Molecule, Drug metabolism, QC, Boehringer Ingelheim, DMPK, Organization, Partnership, Fine chemical, Pharmacokinetics, Genedata

BASEL, Switzerland, Nov. 20, 2023 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Boehringer Ingelheim, one of the largest producers of biopharmaceuticals in the world, has expanded usage of the Genedata platform to include the Drug Metabolism and Pharmacokinetics (DMPK) group in the US. The DMPK US operations use Genedata Biologics® as part of their life-cycle management strategy of critical reagents (including analytical reference standards and drug products) used in the non-clinical and clinical bioanalytical activities of prospective new biopharmaceutical drugs.

Key Points: 
  • The DMPK US operations use Genedata Biologics ® as part of their life-cycle management strategy of critical reagents (including analytical reference standards and drug products) used in the non-clinical and clinical bioanalytical activities of prospective new biopharmaceutical drugs.
  • We have been using Genedata Biologics across our early biologics discovery operations for many years and are very excited to onboard the US-DMPK group as this is a major step towards having complete end-to-end digital tracking of all BI's therapeutic candidates.
  • "After an initial evaluation, the DMPK group was eager to get onto the Genedata Biologics platform and take advantage of having all information pertaining to critical reagents in one place.
  • One of the strengths of Genedata Biologics is the platform's ability to integrate with Boehringer Ingelheim's laboratory instruments, sample management systems, and corporate IT infrastructure.

TransCode Therapeutics Announces Positive Results in Non-human Primates with its Lead Therapeutic Candidate, TTX-MC138

Retrieved on: 
Monday, July 31, 2023
Molecular biology, Real-time, Human, Therapy, Anatomy, Clinical trial, Radiology, Cancer, Transcoding, Physiology, Massachusetts General Hospital, Drug metabolism, RNA, Harvard Medical School, Athinoula A. Martinos Center for Biomedical Imaging, Biomedicine, Patient, DMPK, Hospital, NHP, Pharmaceutical industry, Medical imaging, Pharmacokinetics

BOSTON, July 31, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today positive results with its lead therapeutic candidate, TTX-MC138, in non-human primates (NHPs), showing that the therapeutic effectively engaged its target and showed favorable pharmacokinetics and tissue distribution.

Key Points: 
  • BOSTON, July 31, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today positive results with its lead therapeutic candidate, TTX-MC138, in non-human primates (NHPs), showing that the therapeutic effectively engaged its target and showed favorable pharmacokinetics and tissue distribution.
  • In addition, the pharmacodynamic activity of radiolabeled TTX-MC138 following a microdose injection was determined by measuring inhibition of the therapeutic target, miRNA-10b, using qRT-PCR.
  • Importantly, even at a microdose, the therapeutic showed lasting activity and significantly inhibited its target, miRNA-10b, known to be a driver of metastatic progression in a number of cancers.
  • TransCode is enrolling patients in a first-in-human clinical trial with TTX-MC138 in patients with advanced solid cancers ( https://clinicaltrials.gov/study/NCT05908773?spons=transcode&rank=1 ).

Nitrase Therapeutics Expands Leadership Team with Accomplished Drug Discovery and Development Executives

Retrieved on: 
Wednesday, July 6, 2022
Department, Miami University, Sofinnova, University of Marburg, DMPK, Research, Precision medicine, Head, MJFF, Therapy, Pharmacokinetics, Enzyme, Investment, Metabolomics, BMS, Biomarker, GLOBE, Cancer, Lists of diseases, The Michael J. Fox Foundation, Genentech, Amgen, Neuroscience, SAN, PCT, Sheerin, University of California, San Francisco, Bristol Myers Squibb, Drug discovery, University, Drug metabolism, Cardiovascular disease, CA, Degenerative disease, Vanderbilt University, ICF, Doctor of Philosophy, Pharmaceutical industry, Biochemistry, Chemistry, Merck

Frank and Sheerin each bring over 20 years of experience in drug discovery and development for both biotech and large pharma.

Key Points: 
  • Frank and Sheerin each bring over 20 years of experience in drug discovery and development for both biotech and large pharma.
  • Before Nitrase Therapeutics, Dr. Kayser was the chief scientific officer and senior vice president of drug discovery at BioArdis, where he spearheaded all aspects of small molecule discovery.
  • Prior to joining Nitrase Therapeutics, she served as a senior director of the ICF disease team and translational medicine at Bristol Myers Squibb (BMS).
  • Nitrase Therapeutics is located in Brisbane, CA, and its investors include Sofinnova Partners, AbbVie Ventures, Dementia Discovery Fund, Bristol Myers Squibb, Mission Bay Capital and Alexandria Venture Investments.

Lengo Therapeutics Announces Expansion of its Executive Leadership Team with Appointments in R&D, CMC and Finance

Retrieved on: 
Tuesday, September 14, 2021
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Genetics, Science, Clinical Trials, Aston, Upjohn, R, National, Patient, Alder Biopharmaceuticals, Deloitte, IND, SVP, RAPS, Merck, CVS, Alder, Acalabrutinib, Aston University, Molecular Omics, CMC, Lundbeck, Merck & Co., PDA, Pharmacokinetics, Therapy, University of Washington Department of Bioengineering, NASDAQ, Salk Institute for Biological Studies, Acquisition, Cancer, Wharton School of the University of Pennsylvania, Drug discovery, BTK, Infection, Pharming, Rensselaer Polytechnic Institute, MBA, San Diego State University, Accounting, AstraZeneca, Business, Lengo Petroglyphs, University, Drug development, Technology, Pharmacology, Pharmacy, University of Pennsylvania, Industry, Drug metabolism, Handbook, ACS, Pharmaceutical industry

Lengo Therapeutics, a biopharmaceutical company developing novel precision medicines targeting driver mutations in oncology, today announced the expansion of the Companys executive management team.

Key Points: 
  • Lengo Therapeutics, a biopharmaceutical company developing novel precision medicines targeting driver mutations in oncology, today announced the expansion of the Companys executive management team.
  • Prior to Amgen, Paul served as Executive Director of Preclinical Drug Metabolism at Merck Research Laboratories.
  • Paul is the editor of the Handbook of Drug Metabolism (2019) and has published extensively in the field.
  • Eric Gruff, Ph.D., is SVP of CMC at Lengo Therapeutics.

CN Bio’s PhysioMimix Technology Receives FDA Recognition

Retrieved on: 
Tuesday, January 12, 2021
Biotechnology, FDA, Medical devices, Health, Pharmaceutical, Operating systems, System software, Metabolism, Pharmacokinetics, Drug metabolism, Hepatology, Toxicology, BIOS, Computer architecture, Cn

The first co-published, peer-reviewed research paper between a commercial MPS provider and a regulator, demonstrates that data derived using CN Bios proprietary PhysioMimix system is appropriate for use in drug safety and metabolism applications, evidencing its enhanced performance versus standard techniques.

Key Points: 
  • The first co-published, peer-reviewed research paper between a commercial MPS provider and a regulator, demonstrates that data derived using CN Bios proprietary PhysioMimix system is appropriate for use in drug safety and metabolism applications, evidencing its enhanced performance versus standard techniques.
  • Scientists at the FDA demonstrated CN Bios PhysioMimix MPS technology accurately models drug metabolism and detects compounds known to be toxic to humans.
  • Dr David Hughes, Chief Executive Officer, CN Bio, said: This publication is invaluable in confirming the utility of our system in the labs of the FDA.
  • Characterizing the Reproducibility in Using a Liver Microphysiological System for Assaying Drug Toxicity, Metabolism and Accumulation, Clinical and Translational Science https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.12969
    For more information about CN Bios products and services, visit: https://cn-bio.com/physiomimixooc/

CN Bio to Provide Drug Metabolism and Safety Toxicity Testing Services

Retrieved on: 
Tuesday, October 27, 2020
Health, Medical devices, Other Science, Research, Science, Pharmaceutical, Biotechnology, Health sciences, Toxicology, Medical specialties, Health, Hepatology, Pharmacokinetics, Pharmacology, Metabolism, Hepatotoxicity, Toxicity, Drug metabolism, Drug discovery

CN Bio, a leading 3D cell culture company, that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy and efficiency of drug discovery, today announced the commercial launch of its Drug Metabolism and Safety Toxicity Testing Services.

Key Points: 
  • CN Bio, a leading 3D cell culture company, that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy and efficiency of drug discovery, today announced the commercial launch of its Drug Metabolism and Safety Toxicity Testing Services.
  • Liver toxicity is a principal safety concern during drug discovery and development, with the potential to terminate expensive clinical trials already underway.
  • CN Bios extended portfolio of services offers solutions to many existing workflow challenges including: drug metabolism testing, to study the human metabolism of lead candidates, identify metabolites and correlation with cell health - even for low clearance compounds, and safety toxicity testing, to provide in-depth analysis of acute or chronic drug-induced liver injury using a wide range of endpoints to determine causality and mechanism of toxicity.
  • Through our enhanced drug metabolism and safety toxicity testing services, we enable scientists to take a step beyond what is currently possible with 2D cell culture and animal studies to improve their chances of clinical success.

Worldwide Drug Discovery Services Industry to 2025 - Featuring Domainex, Chempartner & TCG Lifesciences Among Others

Retrieved on: 
Wednesday, September 23, 2020
Health, Pharmaceutical sciences, Pharmaceuticals policy, DMPK, Drug discovery, Medicinal chemistry, Orphan drug, Drug metabolism, Heroin

Increasing R&D spending and initiatives for rare disease and orphan drugs research are set to drive the drug discovery services market.

Key Points: 
  • Increasing R&D spending and initiatives for rare disease and orphan drugs research are set to drive the drug discovery services market.
  • However, the high cost of drug discovery and development and stringent regulations governing drug discovery and animal usage in testing may restrict the growth of this market to a certain extent.
  • Based on type, the drug discovery services market is segmented into medicinal chemistry services, biology services, and drug metabolism and pharmacokinetics (DMPK).
  • North America, which includes the US and Canada, accounted for the largest share of the drug discovery services market.

CN Bio Innovations raises $9 million USD (c. £6.9 million GBP)

Retrieved on: 
Monday, March 2, 2020
Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, Companies, Economy of China, CITIC Securities, CITIC Group, Cn, Drug metabolism

CN Bio Innovations (CN Bio), a leading cell culture company that has developed organ-on-chip laboratory instruments to improve the accuracy and efficiency of drug discovery, today announced it has raised $9 million USD (circa 6.9 million GBP) investment, led by CITIC Securities Investment Co., Ltd., and supported by existing investor CN Innovations Holdings Ltd.

Key Points: 
  • CN Bio Innovations (CN Bio), a leading cell culture company that has developed organ-on-chip laboratory instruments to improve the accuracy and efficiency of drug discovery, today announced it has raised $9 million USD (circa 6.9 million GBP) investment, led by CITIC Securities Investment Co., Ltd., and supported by existing investor CN Innovations Holdings Ltd.
  • CN Bio has also announced the relocation and expansion of its headquarters to the Cambridge Science Park, UK, including 4,000 sq.
  • CN Bios micro-physiological systems enable researchers to study drug metabolism, toxicology and specific disease models on single- and multi-organ systems.
  • Building on over ten years of research and development of organ-on-chip technology, CN Bio is an exciting and promising investment.